54.90
price down icon0.63%   -0.35
after-market アフターアワーズ: 55.25 0.35 +0.64%
loading
前日終値:
$55.25
開ける:
$55.3
24時間の取引高:
677.78K
Relative Volume:
1.24
時価総額:
$1.52B
収益:
$17.16M
当期純損益:
$-163.62M
株価収益率:
-9.0296
EPS:
-6.08
ネットキャッシュフロー:
$-121.61M
1週間 パフォーマンス:
+14.61%
1か月 パフォーマンス:
+11.97%
6か月 パフォーマンス:
+173.00%
1年 パフォーマンス:
+239.94%
1日の値動き範囲:
Value
$51.92
$56.07
1週間の範囲:
Value
$46.85
$56.39
52週間の値動き範囲:
Value
$14.46
$56.39

Anaptysbio Inc Stock (ANAB) Company Profile

Name
名前
Anaptysbio Inc
Name
セクター
Healthcare (1112)
Name
電話
858-362-6295
Name
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Name
職員
136
Name
Twitter
@anaptysbio
Name
次回の収益日
2024-11-08
Name
最新のSEC提出書
Name
ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ANAB
Anaptysbio Inc
54.90 1.53B 17.16M -163.62M -121.61M -6.08
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-10-13 開始されました Barclays Overweight
2025-06-04 アップグレード H.C. Wainwright Neutral → Buy
2025-02-04 開始されました Wolfe Research Outperform
2024-12-11 ダウングレード H.C. Wainwright Buy → Neutral
2024-12-02 ダウングレード BTIG Research Buy → Neutral
2024-07-22 開始されました H.C. Wainwright Buy
2024-07-19 アップグレード JP Morgan Neutral → Overweight
2024-04-16 開始されました Leerink Partners Outperform
2024-04-11 開始されました Wells Fargo Overweight
2024-03-12 アップグレード Wedbush Neutral → Outperform
2024-02-26 開始されました BTIG Research Buy
2024-02-21 開始されました Stifel Buy
2024-02-16 開始されました Piper Sandler Overweight
2023-05-22 アップグレード JP Morgan Underweight → Neutral
2023-05-18 開始されました TD Cowen Outperform
2023-01-06 ダウングレード Raymond James Outperform → Mkt Perform
2022-11-01 アップグレード Guggenheim Neutral → Buy
2022-09-19 再開されました H.C. Wainwright Buy
2022-09-13 ダウングレード Truist Buy → Hold
2022-09-01 開始されました Raymond James Outperform
2022-03-22 ダウングレード Guggenheim Buy → Neutral
2021-06-22 開始されました H.C. Wainwright Buy
2021-05-21 開始されました UBS Neutral
2021-03-16 アップグレード Truist Hold → Buy
2021-03-09 ダウングレード Wedbush Outperform → Neutral
2021-03-08 ダウングレード JP Morgan Overweight → Underweight
2021-02-11 アップグレード JP Morgan Underweight → Overweight
2020-10-27 アップグレード Wedbush Neutral → Outperform
2020-10-14 アップグレード Guggenheim Neutral → Buy
2019-11-08 ダウングレード JP Morgan Overweight → Underweight
2019-11-08 ダウングレード Jefferies Buy → Hold
2019-11-08 ダウングレード SunTrust Buy → Hold
2019-11-08 ダウングレード Wedbush Outperform → Neutral
2019-06-21 ダウングレード Credit Suisse Outperform → Neutral
2019-06-21 ダウングレード Stifel Buy → Hold
2018-12-20 開始されました H.C. Wainwright Buy
2018-11-21 開始されました JP Morgan Overweight
2018-07-19 開始されました Credit Suisse Outperform
2018-04-04 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2018-03-27 繰り返されました Stifel Buy
2018-03-06 繰り返されました Stifel Buy
2018-02-15 繰り返されました SunTrust Buy
2018-01-23 繰り返されました Credit Suisse Outperform
2017-11-15 開始されました SunTrust Buy
2017-11-09 開始されました Jefferies Buy
2017-10-11 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
すべてを表示

Anaptysbio Inc (ANAB) 最新ニュース

pulisher
03:13 AM

Page not foundAirwhon - MarketBeat

03:13 AM
pulisher
03:08 AM

AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - Yahoo Finance

03:08 AM
pulisher
02:21 AM

ANAB: Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline - TradingView

02:21 AM
pulisher
06:47 AM

AnaptysBio stock hits 52-week high at $52.56 By Investing.com - Investing.com South Africa

06:47 AM
pulisher
01:12 AM

Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? - Yahoo Finance

01:12 AM
pulisher
Feb 11, 2026

(ANAB) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Feb 11, 2026
pulisher
Feb 11, 2026

Market Trends: Is AnaptysBio Inc a momentum stockDollar Strength & Real-Time Stock Price Movement Reports - baoquankhu1.vn

Feb 11, 2026
pulisher
Feb 11, 2026

AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighShould You Buy? - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte, Novartis - Barchart.com

Feb 11, 2026
pulisher
Feb 10, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 10, 2026
pulisher
Feb 07, 2026

Momentum Shift: Is AnaptysBio Inc in a consolidation phase2025 Dividend Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 06, 2026

ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 06, 2026
pulisher
Feb 06, 2026

Anaptys Announces Participation at Upcoming Investor Conferences - Sahm

Feb 06, 2026
pulisher
Feb 05, 2026

Biotech firm Anaptys lines up February–March investor events - Stock Titan

Feb 05, 2026
pulisher
Feb 05, 2026

AnaptysBio to participate in investor conferences. CEO to attend for discussions on immunology therapeutics. - Longbridge

Feb 05, 2026
pulisher
Feb 03, 2026

Sentiment Review: Is GTIM in a long term uptrendJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

Biotech Leader Eyes Spinoff Amid Massive Sales Surge - Investor's Business Daily

Feb 03, 2026
pulisher
Feb 03, 2026

Federated Hermes Inc. Increases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat

Feb 03, 2026
pulisher
Jan 31, 2026

Responsive Playbooks and the ANAB Inflection - Stock Traders Daily

Jan 31, 2026
pulisher
Jan 31, 2026

Inflation Data: Will BTCT benefit from rising consumer demandWeekly Stock Analysis & Verified Swing Trading Watchlist - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 30, 2026

H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN

Jan 30, 2026
pulisher
Jan 28, 2026

Can AnaptysBio Inc. reach all time highs this yearQuarterly Trade Summary & Daily Stock Trend Reports - mfd.ru

Jan 28, 2026
pulisher
Jan 26, 2026

Bear Alert: Is AnaptysBio Inc undervalued by DCF analysisDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 24, 2026

AnaptysBio (NASDAQ:ANAB) Downgraded to Buy Rating by Wall Street Zen - MarketBeat

Jan 24, 2026
pulisher
Jan 23, 2026

ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup - ChartMill

Jan 23, 2026
pulisher
Jan 22, 2026

Assessing AnaptysBio (ANAB) Valuation As Technical Strength Meets Improving Profitability Prospects - Sahm

Jan 22, 2026
pulisher
Jan 21, 2026

CD122’s double whammy makes for intriguing target - BioWorld MedTech

Jan 21, 2026
pulisher
Jan 20, 2026

Understanding the Setup: (ANAB) and Scalable Risk - Stock Traders Daily

Jan 20, 2026
pulisher
Jan 20, 2026

Treasury Yields: Will AnaptysBio Inc benefit from geopolitical trendsJuly 2025 Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Jan 20, 2026
pulisher
Jan 20, 2026

Barclays Raises Price Target for AnaptysBio (ANAB) to $78.00 | A - GuruFocus

Jan 20, 2026
pulisher
Jan 18, 2026

Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative? - simplywall.st

Jan 18, 2026
pulisher
Jan 17, 2026

ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment - Chartmill

Jan 17, 2026
pulisher
Jan 17, 2026

AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty - AD HOC NEWS

Jan 17, 2026
pulisher
Jan 17, 2026

Market Leaders: Is AnaptysBio Inc stock a good dividend stock2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 16, 2026

Anaptysbio director Marquet sells $530k in shares By Investing.com - Investing.com Nigeria

Jan 16, 2026
pulisher
Jan 16, 2026

AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares - MarketBeat

Jan 16, 2026
pulisher
Jan 16, 2026

Anaptysbio director Marquet sells $530k in shares - Investing.com

Jan 16, 2026
pulisher
Jan 16, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Jan 16, 2026
pulisher
Jan 15, 2026

Breakout Zone: Can AnaptysBio Inc generate free cash flowWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 15, 2026

AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3%Time to Sell? - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

Rally Mode: Is AnaptysBio Inc a momentum stock2025 Winners & Losers & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 13, 2026

AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf - MarketBeat

Jan 13, 2026
pulisher
Jan 13, 2026

ANAB: Separation into two focused entities targets value creation, with major clinical and royalty catalysts ahead - TradingView — Track All Markets

Jan 13, 2026
pulisher
Jan 13, 2026

What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally - AOL.com

Jan 13, 2026
pulisher
Jan 12, 2026

AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2%Time to Buy? - MarketBeat

Jan 12, 2026
pulisher
Jan 12, 2026

AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation By Investing.com - Investing.com Canada

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock By Investing.com - Investing.com Nigeria

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Australia

Jan 12, 2026
pulisher
Jan 11, 2026

What Investors Should Know About a $163K AnaptysBio Insider Sale - sharewise.com

Jan 11, 2026

Anaptysbio Inc (ANAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Anaptysbio Inc (ANAB) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Marquet Magda
Director
Jan 15 '26
Option Exercise
26.11
11,000
287,210
20,930
Marquet Magda
Director
Jan 15 '26
Sale
48.23
11,000
530,531
9,930
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):